|
Mutation Information
|
Mutation Site
|
S147G |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.S147G+in.G140S+in.L74M;in.S147G+in.E138K+in.L74M;in.Q148K+in.S147G+in.G140S+in.L74M |
|
Genotype/Subtype
|
B;C;AG |
|
Viral Reference
|
AF324493.2;
AF096341.1 |
|
Relevant Drug
|
cabotegravir (CAB);elvitegravir (EVG);dolutegravir (DTG);raltegravir (RAL);bictegravir (BIC) |
|
Country
|
Canada |
Literature Information
|
PubMed PMID
|
30119633
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
Retrovirology |
|
Title
|
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. |
|
Author
|
Oliveira M,Ibanescu RI,Anstett K,Mésplède T,Routy JP,Robbins MA,Brenner BG,Montreal Primary HIV (PHI) Cohort Study Group. |
|
Evidence
|
With DTG and BIC, solitary R263K (n = 27), S153F/Y (n = 7) H51Y (n = 2), Q146 R (n = 3) or S147G (n = 1) mutations conferred low-level (< 3-fold) resistance at weeks 36-46.
|
|
|
HIV Mutation Detail Information